Iovance Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 9.56 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.33B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w...